Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Annovis Bio, Inc. Common Stock (NY:ANVS)

2.050 -0.120 (-5.53%)
Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stocks Deepen Losses As Treasury Yields Soar
The Dow Jones Industrial Average is deepening this morning's losses, down nearly 320 points at last check, as the Federal Open Market Committee's (FOMC) two-day policy meeting gets underway. 
Via Talk Markets
S&P 500 Down 0.6%; Crude Oil Falls Sharply
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping over 100 points on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
  
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Why Zscaler Is Trading Higher By Around 19%, Here Are 44 Stocks Moving In Friday's Mid-Day Session
Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares jumped 70% to $2.1750 after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in cash. 
Via Benzinga
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
FDA Gives Green Signal To Annovis Bio's Parkinson's Trial With Buntanetap
Via Benzinga
Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday
Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in... 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to... 
Via Benzinga
Annovis Shares Gain As Late-Stage Parkinson's Disease Study Takes-off
Annovis Bio, Inc. (NYSE: ANVS) has initiated patient dosing in the Phase 3 clinical trial evaluating buntanetap in early Parkinson's Disease (PD). The Phase 3 trial is designed to evaluate the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2022
  
Via Benzinga
Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron
Recent publishing of Longeveron Inc.’s (NASDAQ: LGVN) 
Via Benzinga
Dear AMC Stock Fans, Mark Your Calendars for Aug. 4
AMC Entertainment (AMC) stock is in the news today as investors in the theater company prepare for a potential catalyst coming next month! 
Via InvestorPlace
Annovis Bio (ANVS) Stock Soars 6% on Positive FDA Update
Annovis Bio (ANVS) stock is soaring higher on Thursday following a positive update from the FDA for its buntanetap clinical trial. 
Via InvestorPlace
Annovis Bio Gets FDA Nod For Late-Stage Parkinson Disease Study Amendments
The United States Food and Drug Administration (FDA) announced clearance for amendments to Annovis Bio’s (NYSE: ANVS) Phase 3 clinical study of Buntanetap for the treatment of Parkinson's disease. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
83 Biggest Movers From Yesterday
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly... 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
Berwyn, Pennsylvania--(Newsfile Corp. - April 28, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)
Berwyn, Pennsylvania--(Newsfile Corp. - March 18, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022
Berwyn, Pennsylvania--(Newsfile Corp. - March 8, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference
Berwyn, Pennsylvania--(Newsfile Corp. - March 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease
Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.